Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04836546 · ClinicalTrials.gov registry record · NA
Eversense® Non-adjunctive Use Post Approval Study
A NA study of Diabetes, sponsored by Senseonics.
- Active
- Registry status
- NA
- Development phase
- 925
- Enrollment target
- 20
- Study locations
NCT04836546 is a NA study of Diabetes that is active but no longer recruiting, run by Senseonics. The registered enrollment target is 925 participants, below the 3,026-participant average among 338 other Diabetes trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04836546, a NA study of Diabetes, is active but no longer recruiting, sponsored by Senseonics.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 925 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effectiveness of diabetes with the Eversense CGM System non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants with either Type 1 or Type 2 diabetes. Subjects will serve as their own control, with their baseline based on using SMBG to manage their diabetes for the first 6 months followed by using Eversense CGM System non-adjunctively for the second 6 months. Total follow-up duration is 12 months. The investigation will include both clinic visits and home use of Eversense CGM System. The nonadjunctive phase will have two sensors, up to 90-day duration, inserted sequentially. All care decisions specific to diabetes will be based on blood glucose (BG) values in the first phase and the Eversense CGM system values in the second phase.
Conditions Studied
Interventions
- DEVICE Blood glucose meter
- DEVICE Eversense CGM System
Study Locations (20)
Florida
- The Center for Diabetes and Endocrine Care - Fort Lauderdale
- MedCare Research - Miami
- Miami Lakes Clinical Trials INC - Miami Lakes
Connecticut
- CMR of Greater New Haven - Hamden
- Chase Medical Research - Waterbury
North Carolina
- Physician's East Endocrinology - Greenville
- Superior Clinical Research - Smithfield
Texas
- Texas Diabetes and Endocrinology - Austin
- Southwest Family Medicine Associates - Dallas
California
- LA Universal Research Center, Inc. - Los Angeles
Colorado
- Denver Endocrinology, Diabetes & Thyroid Center - Englewood
Georgia
- Atlanta Diabetes Associates - Atlanta
Idaho
- Rocky Mountain Clinical Research - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 925 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04836546
The ClinicalTrials.gov registry entry for NCT04836546 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 925 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,026-participant average among 338 other Diabetes trials with a reported enrollment target (69% lower). The listed sponsor is Senseonics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Blood glucose meter is the first listed.
NCT04836546 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Connecticut, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04836546 about?
NCT04836546 is a clinical study titled "Eversense® Non-adjunctive Use Post Approval Study". This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effectiveness of diabetes with the Eversense CGM System non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter...
What is the current status of trial NCT04836546?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 925 participants. The study started on 2021-04-13. Estimated completion is 2026-03-31.
What conditions does trial NCT04836546 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT04836546?
The interventions under investigation include: Blood glucose meter (DEVICE), Eversense CGM System (DEVICE).
Who is sponsoring clinical trial NCT04836546?
This trial is sponsored by Senseonics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04836546 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.